There seem to be an awful lot of indications for the cd56 marker. Any educated guesses about the potential market size?
hmm market projected to be 5.8billion in 2018 for multiple myeloma
non small cell lung cancer market projected to be 6.9billion in 2019
so 5.8 + 6.9 = is a nearly $13billion market potential for n901
if IMGN can capture a portion of that total market, the income would eclipse the royalties from TDM1, unfortunately 2019 is still a few years off. Luckily it will be approved by that time.
Just more reason to keep some core shares for the long term